Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

A media report stated that an activist investor is accumulating a stake in the Wegovy maker. Wegovy and Ozempic maker Novo ...

While Americans understand the benefits of GLP-1 agonist medications, 83% of Americans are unwilling to pay more than $100 in ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...

Why Might Some People Opt to Take an Oral Version of Wegovy Instead of Injections? There are multiple reasons why someone ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...